1. Home
  2. INSM vs PNR Comparison

INSM vs PNR Comparison

Compare INSM & PNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • PNR
  • Stock Information
  • Founded
  • INSM 1988
  • PNR 1966
  • Country
  • INSM United States
  • PNR United Kingdom
  • Employees
  • INSM N/A
  • PNR N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • PNR Industrial Machinery/Components
  • Sector
  • INSM Health Care
  • PNR Industrials
  • Exchange
  • INSM Nasdaq
  • PNR Nasdaq
  • Market Cap
  • INSM 12.6B
  • PNR 13.3B
  • IPO Year
  • INSM 2000
  • PNR N/A
  • Fundamental
  • Price
  • INSM $65.08
  • PNR $93.46
  • Analyst Decision
  • INSM Strong Buy
  • PNR Buy
  • Analyst Count
  • INSM 16
  • PNR 16
  • Target Price
  • INSM $95.36
  • PNR $107.33
  • AVG Volume (30 Days)
  • INSM 2.5M
  • PNR 1.6M
  • Earning Date
  • INSM 05-08-2025
  • PNR 04-22-2025
  • Dividend Yield
  • INSM N/A
  • PNR 1.07%
  • EPS Growth
  • INSM N/A
  • PNR 2.96
  • EPS
  • INSM N/A
  • PNR 3.87
  • Revenue
  • INSM $381,030,000.00
  • PNR $4,076,000,000.00
  • Revenue This Year
  • INSM $30.36
  • PNR $2.16
  • Revenue Next Year
  • INSM $115.55
  • PNR $3.88
  • P/E Ratio
  • INSM N/A
  • PNR $24.16
  • Revenue Growth
  • INSM 20.77
  • PNR N/A
  • 52 Week Low
  • INSM $21.92
  • PNR $72.63
  • 52 Week High
  • INSM $84.91
  • PNR $110.71
  • Technical
  • Relative Strength Index (RSI)
  • INSM 35.80
  • PNR 63.02
  • Support Level
  • INSM $63.81
  • PNR $91.18
  • Resistance Level
  • INSM $73.39
  • PNR $94.64
  • Average True Range (ATR)
  • INSM 2.53
  • PNR 2.12
  • MACD
  • INSM -0.38
  • PNR 0.73
  • Stochastic Oscillator
  • INSM 13.26
  • PNR 88.52

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About PNR Pentair plc.

Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Pentair's business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2024.

Share on Social Networks: